

Supplementary table 1. Sub-group analysis of patients receiving initial calcineurin inhibitor-free regime with basiliximab (N=64)

Baseline Characteristics	Early basiliximab (<24 hours) (N=50)	Late basiliximab (≥24 hours) (N=14)	<i>P</i> value
Age	Mean (SD)	Mean (SD)	
Recipient	46 (14)	49 (11)	0.61
Donor	37 (13)	35 (11)	0.58
BMI (kg/m ²)	25.3 (3.8)	23.6 (4.4)	0.15
Gender (female)	N (%)	N (%)	
Recipient	15 (30%)	4 (29%)	0.92
Donor	21 (42%)	6 (43%)	0.95
Cause of Heart Failure N (%)			0.72
Ischemic Cardiomyopathy	11 (22%)	1 (7%)	
Dilated Cardiomyopathy	26 (52%)	8 (57%)	
Hypertrophic Cardiomyopathy	2 (4%)	0 (0%)	
Restrictive Cardiomyopathy	3 (6%)	1 (7%)	
Congenital Heart Disease	6 (12%)	3 (21%)	
Others	2 (4%)	1 (7%)	
VAD as a bridge N (%)	24 (48%)	6 (43%)	0.73
EBV IgG positive N (%)			
Recipient	46 (92%)	13 (93%)	0.92
Donor	43 (86%)	13 (93%)	0.72
CMV status N (%)			0.74
D- / R-	7 (14%)	3 (21%)	
D- / R+	13 (27%)	2 (14%)	
D+ / R-	12 (25%)	3 (21%)	
D+ / R+	17 (35%)	6 (43%)	
Donor specific antibody N (%)			0.21
None	30 (61%)	6 (46%)	
Weak	2 (4%)	2 (15%)	
Moderate	12 (25%)	5 (39%)	
Strong	5 (10%)	0 (0%)	
HLA mismatch	4 (1)	5 (1)	0.14
Total Ischemic time (min)	186 (84)	203 (75)	0.39
Immunosuppression regimens			
Pre-transplantation			
Tacrolimus N (%)	8 (16%)	8 (57%)	<0.01
Dose (mg) Mean (SD)	3.1 (0.8)	3.0 (0.9)	0.65
Post-transplantation			
Tacrolimus N (%)	12 (24%)	2 (14%)	
	Mean (SD)	Mean (SD)	
Starting day	3 (2)	4 (1)	0.45
Starting dose (mg/kg/day)	0.045 (0.016)	0.025 (0.018)	0.12
Week 1 level (ng/mL)	6.9 (3.7)	5.6 (5.0)	0.67
Week 2 level (ng/mL)	9.4 (4.2)	7.9 (4.2)	0.64
Week 3 level (ng/mL)	13.1 (4.8)	13.1 (5.3)	0.98
Week 4 level (ng/mL)	12.4 (4.9)	14.7 (5.1)	0.56

Everolimus N (%)	38 (76%)	12 (86%)	
	Mean (SD)	Mean (SD)	
Starting day	2 (1)	2 (1)	0.07
Starting dose (mg/day)	3.5 (1.5)	3.5 (1.5)	0.93
Week 1 level (ng/mL)	6.0 (3.0)	5.5 (2.8)	0.63
Week 2 level (ng/mL)	8.9 (4.7)	9.2 (3.5)	0.87
Week 3 level (ng/mL)	9.2 (2.5)	11.6 (4.1)	0.09
Week 4 level (ng/mL)	10.0 (4.8)	8.4 (3.8)	0.47

Abbreviation:

BMI, Body Mass Index

CMV, Cytomegalovirus

D +/-, Donor status positive or negative

R +/-, Recipient status positive or negative

EBV, Epstein–Barr virus

HLA, Human Leukocyte Antigen

VAD, Ventricular assist device